

MEDICAL PRESCRIPTION FORM

CONSULTATION CERTIFICATE / CERTIFICAT OF INFORMATION AND CONSENT FOR TESTING Laboratoire Cerba Customer relation service Tél.: +33 (0)1 34 40 97 76 Fax: +33 (0)1 34 40 21 29 Email: intgb@lab-cerba.com

FETAL SEX DETERMINATION FROM MATERNAL BLOOD Mandatory completion of the signed consultation certificate and consent form (Document below)

LABORATORY AND TESTING			
Customer no.			Sampling time h
PATIENT		Prescriber	
LAST NAME		LAST NAME	
FIRST NAME		FIRST NAME	
Birth name		Address	
		•	. Country
Address			
City Country			
Date of birth:			
		Signature:	
CURENT PREGNANCY			
Date of the last menstrual period			
□ Singleton pregnancy □ Multiple pregnancy			
Is prenatal diagnosis by invasive procedure planned?			
□ X-linked recessive genetic disease (RLX), specify			
□ X-linked dominant genetic disease (DLX), specify			
Congenital adrenal hyperplasia (couple at risk)			
Chromosomal abnormality involving X, specify			
Abnormal external genitalia on ultrasound			
Discordance ultrasound sex vs chromosomal sex			
Suspicion on an (unidentified) recessive X-linked genetic disease (RLX), specify			
Other, specify			
INFORMATION FOR THE PATIENT, CERTIFICATE OF MEDICAL CONSULTATION AND CONSENT FOR TESTING			
I, the undersigned, Dr/Prgenetic counsellor under the			
responsibility of Dr/Pr, hereby certify that I have received Mrs (<i>surname, first name, date of birth</i>)			
Determining the sex of your foetus is useful for managing your pregnancy, particularly if you are considering early prenatal diagnosis. There are several ways of doing			
this:			
• Fetal ultrasound can be used to determine the sex of the foetus, but to be as reliable as possible it can only be carried out from the 14th week of amenorrhoea, which is not compatible with early prenatal diagnosis.			
 A sample of foetal tissue is taken to establish the chromosomal sex of the foetus (foetal karyotype). This sample can be taken from the 11th week of amenorrhoea 			
(chorionic villus biopsy) or later (amniotic fluid by amniocentesis) from the 14th week. However, these invasive procedures carry risks, particularly of foetal loss			
(around 1 to 2%).			
To find out the sex of your foetus at an early stage (before the 14th week of amenorrhoea) without having to undergo an invasive procedure, you can have its sex determined by genetic analysis of the foetal DNA circulating in your blood. This test can also be useful if you have difficulty interpreting a foetal ultrasound scan. It			
is a simple blood test that poses no risk to you		,	, , , , , , , , , , , , , , , , , , , ,
I, the undersigned, Mrs (surname, first name, date of birth)			
• Consent to the collection and performance of this molecular genetic test, which will be carried out by a medical biology laboratory authorised by the French authorities to carry it out. This is a simple blood test that poses no risk to my foetus.			
The results of this test will be given to me and explained by the prescribing doctor (or by delegation to the genetic counsellor) in the context of a genetic			
consultation. The original of this document is kept in my medical file. A copy of this document is given to me and to the practitioner who is to carry out the tests.			
The medical biology laboratory where the practitioner who carried out the tests works will keep this document under the same conditions as the test report. I have had the opportunity to ask any questions I may have had to the geneticist or genetic counsellor who prescribed this examination and I have received full and			
	have had to the geneticist or gene	tic counsellor who prescribed this exa	mination and I have received full and
adequate answers. Done in	, on		
PATIENT'S SIGNATURE		AL REPRESENTATIVE(S)	PRESCRIBER'S SIGNATURE
Surname, First name, Date of birth	Surname, First name, Date of birth		Surname, First name
,,, _,, _		·	,
	Lien Relationship to the patient (if patier	nt minor or adult under guardianship) :	

Cerba Laboratory is responsible for processing your personal data provided in this form as the data controller, in order to perform tests, interpret them, transmit results, and manage the laboratory's administrative tasks. If you are a patient, your data may then be reused for anonymization purposes for scientific research, quality control, statistical studies, or satisfaction surveys. To learn more about how your personal data is processed, your rights, and research projects' tabs. To exercise your rights of opposition, contact our Data Protection Officer (DPO) at: rpd.cerba@laboerba.com / CERBA–RPD – ZAC DES EPINEAUX 10-12 Avenue ROLAND MORENO CS 51312 95740 FREPTLON. // I you are a patient, in accordance with applicable regulations, once your tests are completed, any remaining samples from your tests will be disposed of . However, they may be kept for use in scientific research or quality control purposes, either directly or after transfer to third parties, in strict compliance with medical confidentiality. You may object to such use by simply making a request to our DPO (contact details above).